GLPG2737 Add-on Increases Effectiveness of Orkambi for Cystic Fibrosis, Phase 2 Results Show
News
Adding GLPG2737, Galapagos’ investigational CFTR corrector, to Vertex’s Orkambi (lumacaftor/ivacaftor) enhances the effectiveness of the treatment in cystic fibrosis patients with two copies of the F508del mutation, topline results from ... Read more